Acute hepatitis A in international travellers: a GeoSentinel analysis, 2008-2020.
COVID-19
endemicity
epidemiology
hepatitis A vaccine
immunization
Journal
Journal of travel medicine
ISSN: 1708-8305
Titre abrégé: J Travel Med
Pays: England
ID NLM: 9434456
Informations de publication
Date de publication:
21 03 2022
21 03 2022
Historique:
received:
12
11
2021
revised:
20
01
2022
accepted:
24
01
2022
pubmed:
9
2
2022
medline:
2
4
2022
entrez:
8
2
2022
Statut:
ppublish
Résumé
Non-immune international travellers are at risk of acquiring hepatitis A. Although hepatitis A vaccination is recommended for unvaccinated travellers to high or intermediate hepatitis A virus endemicity, compliance with this recommendation is not universal.The main objective was to describe the demographic and travel characteristics of international travellers infected with hepatitis A during travel. Available data on travellers with confirmed (positive molecular test) or probable (symptomatic individuals with a single positive IgM test) hepatitis A diagnosed during and after travel from January 2008 to December 2020 were obtained from the GeoSentinel Surveillance Network database. We analysed demographic and travel characteristics of infected travellers. Among 254 travellers with hepatitis A (185 confirmed and 69 probable), the median age was 28 years (interquartile range: 19-40), 150 (59%) were male, and among 54 travellers with information available, 53 (98%) were unvaccinated. The most common reasons for travel included tourism (n = 120; 47%) and visiting friends or relatives (VFR; n = 72; 28%). About two-thirds of VFR travellers with hepatitis A (n = 50; 69%) were younger than 20 years old. Hepatitis A was acquired most frequently in South-Central Asia (n = 63; 25%) and sub-Saharan Africa (n = 61; 24%), but 16 travellers (6%) acquired hepatitis A in regions with low endemicity including Western Europe (n = 7; 3%), the Caribbean (n = 6; 2%) and North America (n = 3; 1%). Median duration from illness onset to GeoSentinel site presentation was ~7 days (interquartile range : 4-14 days). Among 88 travellers with information available, 59% were hospitalized. Despite availability of highly effective vaccines, travellers still acquire hepatitis A, even when traveling to low-endemicity destinations. Providing pre-departure hepatitis A vaccine to susceptible travellers is crucial to reducing travel-associated hepatitis A and should be offered to all travellers as part of the pre-travel consultation, regardless of destination.
Sections du résumé
BACKGROUND
Non-immune international travellers are at risk of acquiring hepatitis A. Although hepatitis A vaccination is recommended for unvaccinated travellers to high or intermediate hepatitis A virus endemicity, compliance with this recommendation is not universal.The main objective was to describe the demographic and travel characteristics of international travellers infected with hepatitis A during travel.
METHODS
Available data on travellers with confirmed (positive molecular test) or probable (symptomatic individuals with a single positive IgM test) hepatitis A diagnosed during and after travel from January 2008 to December 2020 were obtained from the GeoSentinel Surveillance Network database. We analysed demographic and travel characteristics of infected travellers.
RESULTS
Among 254 travellers with hepatitis A (185 confirmed and 69 probable), the median age was 28 years (interquartile range: 19-40), 150 (59%) were male, and among 54 travellers with information available, 53 (98%) were unvaccinated. The most common reasons for travel included tourism (n = 120; 47%) and visiting friends or relatives (VFR; n = 72; 28%). About two-thirds of VFR travellers with hepatitis A (n = 50; 69%) were younger than 20 years old. Hepatitis A was acquired most frequently in South-Central Asia (n = 63; 25%) and sub-Saharan Africa (n = 61; 24%), but 16 travellers (6%) acquired hepatitis A in regions with low endemicity including Western Europe (n = 7; 3%), the Caribbean (n = 6; 2%) and North America (n = 3; 1%). Median duration from illness onset to GeoSentinel site presentation was ~7 days (interquartile range : 4-14 days). Among 88 travellers with information available, 59% were hospitalized.
CONCLUSIONS
Despite availability of highly effective vaccines, travellers still acquire hepatitis A, even when traveling to low-endemicity destinations. Providing pre-departure hepatitis A vaccine to susceptible travellers is crucial to reducing travel-associated hepatitis A and should be offered to all travellers as part of the pre-travel consultation, regardless of destination.
Identifiants
pubmed: 35134210
pii: 6520887
doi: 10.1093/jtm/taac013
pmc: PMC9383360
pii:
doi:
Substances chimiques
Hepatitis A Vaccines
0
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Public Health Agency of Canada
Organisme : ISTM
Organisme : CDC HHS
ID : U50CK00189
Pays : United States
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of International Society of Travel Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Vaccine. 2004 Jan 26;22(5-6):592-3
pubmed: 14994738
J Travel Med. 2009 Jul-Aug;16(4):233-8
pubmed: 19674261
Ann Saudi Med. 1997 Mar;17(2):200-3
pubmed: 17377430
MMWR Morb Mortal Wkly Rep. 2018 Nov 02;67(43):1216-1220
pubmed: 30383742
Vaccines (Basel). 2016 Mar 11;4(1):
pubmed: 26978406
J Travel Med. 2010 Nov-Dec;17(6):387-91
pubmed: 21050318
Clin Infect Dis. 2022 Mar 9;74(5):901-904
pubmed: 34097015
Epidemiol Rev. 2006;28:101-11
pubmed: 16775039
Public Health. 2019 Mar;168:150-156
pubmed: 30442468
Cold Spring Harb Perspect Med. 2018 Oct 1;8(10):
pubmed: 29500305
P T. 2016 Jul;41(7):426-36
pubmed: 27408519
MMWR Recomm Rep. 2020 Jul 03;69(5):1-38
pubmed: 32614811
Euro Surveill. 2012 May 31;17(22):
pubmed: 22687916
J Travel Med. 2007 Jan-Feb;14(1):31-6
pubmed: 17241251
J Travel Med. 2020 Dec 23;27(8):
pubmed: 33247586
J Travel Med. 2013 Nov-Dec;20(6):394-9
pubmed: 24165384
World J Hepatol. 2012 Mar 27;4(3):68-73
pubmed: 22489258
Epidemiol Infect. 2016 Dec;144(16):3554-3563
pubmed: 27574034
JAMA. 2001 Dec 19;286(23):2968-73
pubmed: 11743837
Am J Public Health. 2019 Sep;109(S4):S297-S302
pubmed: 31505154
Int J Infect Dis. 2018 Mar;68:13-17
pubmed: 29292043
Sci Rep. 2018 Nov 12;8(1):16696
pubmed: 30420608
Pediatrics. 2007 Jul;120(1):189-99
pubmed: 17606579
Epidemiol Infect. 2004 Dec;132(6):1005-22
pubmed: 15635957
World J Clin Cases. 2018 Nov 6;6(13):589-599
pubmed: 30430114
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
Vaccine. 1992;10 Suppl 1:S160-8
pubmed: 1335652